Request Appointment Patient Portal Telemedicine Consent Physician Referrals Research Referrals
  • facebook.pngfacebook.png
  • twitter.pngtwitter.png
  • linkedin.pnglinkedin.png
Texas Liver Institute
  • Home
  • About
    • Research
    • Austin Clinic
    • Dallas Clinic
    • Vision & Mission
    • Physicians & Providers
    • Affiliations
    • Events
    • Disclosures
  • Services
    • Clinical Services
    • Nutrition Information
  • Education
    • About Your Liver
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C (HCV)
    • Chronic Hepatitis C
    • Autoimmune Hepatitis
    • Cirrhosis
    • Fatty Liver Disease
    • Liver Cancer
    • Hemochromatosis
    • Hepatocellular Carcinoma (HCC)
    • Primary Biliary Cholangitis (PBC)
    • Primary Sclerosing Cholangitis (PSC)
    • Health and Wellness
  • Research Studies
  • Patient Resources
    • Patient Portal
    • Telemedicine Consent
    • What to Bring to Your Appointment
    • What to Expect During Your Visit
    • Working with Your Insurance
    • Our Financial Policies
    • Understanding Your Bill
    • Privacy Policy and HIPAA
    • FAQs
    • Patient Forms
  • Liver Updates
    • Liver News
    • Newsletters
    • Video Lectures
    • Slide Presentations
    • Most Recent Publications
  • Contact
    • Contact Us
    • Request Appointment!
    • Physican Referrals
    • Careers

May 05 2015

UNITY-1: Fixed-dose combo yields high SVR12 in HCV patients without cirrhosis

Sean Hendrickson

Media

Treatment-naive and experienced patients with chronic hepatitis C virus genotype 1 infection without cirrhosis...

Read More

May 05 2015

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) | BMS Newsroom

Sean Hendrickson

Media

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients...

Read More

May 05 2015

Merck releases phase III data of grazoprevir/elbasvir to treat chronic hepatitis C virus – Pharmaceutical Business Review

Sean Hendrickson

Media

Merck has released first presentations of data from C-EDGE phase III clinical trial of...

Read More

May 05 2015

Janssen announces results for its HCV treatment simeprevir

Sean Hendrickson

Media

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson...

Read More

May 05 2015

Could Merck & Co., Inc.’s (MRK) Hepatitis C Drugs Be A Threat To Gilead Sciences, Inc. (GILD) And AbbVie Inc (ABBV)?

Sean Hendrickson

Media

Bidness Etc takes a look at how Merck’s new drug is different from the...

Read More

May 05 2015

HIV & AIDS Information :: When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

Sean Hendrickson

Media

More than 70% of people with chronic genotype 1 hepatitis C who did not...

Read More

May 05 2015

HIV & AIDS Information :: Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants

Sean Hendrickson

Media

An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response...

Read More

May 05 2015

HCV Drug Combo Succeeds in Advanced Disease | Medpage Today

Sean Hendrickson

Media

VIENNA — An investigational drug combination had high efficacy among patients with cirrhosis associated...

Read More

May 05 2015

Need for Speed Defines Hepatitis C Race for Gilead, Achillion – Bloomberg Business

Sean Hendrickson

Media

With Merck & Co. poised to disrupt competitors with new hepatitis C drugs, rivals...

Read More

May 05 2015

ALLY-1 Results: More Good News on Hep C

Sean Hendrickson

Media

Results of trials of antivirals to treat hepatitis C infections are dominating the proceedings...

Read More
Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
Next
San Antonio

607 Camden St
Suite 101
San Antonio, Texas 78215

Phone : 210-253-3426

Fax : 210-227-6951

Austin

7940 Shoal Creek Blvd
Suite 205
Austin, Texas 78757

Phone : 512-454-8378

Fax : 512-454-8375

Dallas

7515 Greenville Ave
Suite 600
Dallas, Texas 75231

Phone : 214-945-2521

Fax : 214-945-2524

Patient Education

  • About Your Liver
  • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C (HCV)
    • Chronic Hepatitis C
    • Autoimmune Hepatitis
  • Fatty Liver Disease
  • Liver Cancer
  • Cirrhosis
  • Hemochromatosis
  • PBC/PSC

Appointments

  • Schedule an Appointment!
  • What to Bring to Your Appointment
  • What to Expect During Your Visit
  • Working with Your Insurance
  • Our Financial Policies
  • Privacy Policy and HIPAA
  • FAQs
  • Patient Forms

Contacts

San Antonio

607 Camden St
Suite 101
San Antonio, Texas 78215

Phone : 210-253-3426

Fax : 210-227-6951

Austin

7940 Shoal Creek Blvd
Suite 205
Austin, Texas 78757

Phone : 512-454-8378

Fax : 512-454-8375

Dallas

7515 Greenville Ave
Suite 600
Dallas, Texas 75231

Phone : 214-945-2521

Fax : 214-945-2524


Disclosures
Copyright © 2020 Texas Liver Institute All Rights Reserved
Texas Liver Institute